Study Detected drug relieves allergic asthma

Study: Novel drug helps with allergic asthma

Allergic asthma is the most common form of bronchial asthma. In some cases, the symptoms are already mitigated by adapting the lifestyle. Usually, however, the patients are also treated with medication. According to a study, a new active ingredient helps particularly well to weaken the symptoms.

One of the most common diseases worldwide
With around 300 million people affected, asthma is one of the most common diseases worldwide. Allergic asthma is considered the most common form of bronchial asthma. The underlying allergies may be diverse, but very often asthma is associated with hay fever. In addition to the drug treatment is also an adaptation of the lifestyle of great importance in the therapy. So the triggers of the allergy should be avoided as much as possible. The consequences of the illness, such as shortness of breath and cough, are very stressful for most people affected. Asthma can even lead to impaired lung function in the longer term. In the future, a new therapeutic concept should help to control the inflammation of the respiratory tract that occurs in allergic asthma and thus to alleviate the course of the disease.

Therapy is often unsatisfactory
According to a study, the symptoms in asthmatic patients weakened enormously when they were given the preparation SB010, reports the Austrian "Standard". The results of the study were recently published in the renowned journal "New England Journal of Medicine". Professor Harald Renz from the Institute of Laboratory Medicine at the Philipps-University Marburg explained: "The therapy of severe forms of allergic asthma is currently unsatisfactory." For several years, the research group of Renz is researching a new treatment option: "Our drug SB010 is the first example of a completely new drug class, the DNAzyme, "says Renz. By this we mean artificial DNA molecules that are enzymatically active. These DNAzymes are particularly targeted. "That makes them the ideal drug candidates for new, highly effective and low-side-effects medicines," said Renz.

Drug reduces symptoms by up to 34 percent
SB010 is reported to inhibit a protein that triggers inflammation and is therefore responsible for typical asthma symptoms. The efficacy of the new therapeutic was tested in a Phase II human study. The study was conducted as a randomized double-blind study at seven German centers under the scientific leadership of Norbert Krug, medical director at the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) in Hanover. It showed that a 28-day treatment with SB010 inhalations led to a significant improvement in lung function. The symptoms of the asthma patients weakened by up to 34 percent. In addition, the preparation proved to be safe and well tolerated. Study leader Krug emphasized: "According to the latest research results, it can be assumed that about 50 percent of all asthmatics suffer from allergic asthma." The physician also said: "I think that further clinical trials on SB010 with larger patient groups with asthma are extremely sensible." (Ad)

/ Span>